May 31, 2011 — UltraSPECT, a provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces a multi-year distribution agreement with nuclear pharmacy network UPPI LLC for exclusive leasing and/or non-exclusive sale of UltraSPECT’s cardiac and bone imaging applications in the United States.
Ushering molecular imaging into a new age of precision and efficiency, UltraSPECT’s growing product line utilizes the company’s innovative wide-beam reconstruction (WBR) technology to enhance the performance of gamma cameras and PET scanners. The technology will cut either standard radiopharmaceutical dose requirements or imaging procedure time in half with no decrease in image quality, while enhancing image resolution. In some cases, exams can be performed in as little as a quarter of the standard procedure time. Additionally, advanced new UltraSPECT applications support a 50 percent reduction in both dose and procedure time.
UltraSPECT WBR’s lower dose requirements offer the benefit of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users the result is enhanced equipment utilization, revenues and patient satisfaction and referrals.
UltraSPECT’s WBR product line is compatible with most major manufacturers’ NM and PET systems as well as all clinical software packages. The technology is a far more cost effective dose reduction alternative to today’s new low-dose SPECT cameras with multiple focused detectors. WBR’s half-dose, half-time and quarter-time capabilities are already successfully utilized in hundreds locations throughout the United States and Europe.
For more information: www.UPPI.org, www.ultraspect.com
April 10, 2024 
![(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.](/sites/default/files/styles/feed_medium/public/PET%20Tracers.jpeg?itok=P5Di6MIe)
